DRG® Neopterin (EIA-2949)

Revised 2 Feb. 2011 rm (Vers. 12.1) **RUO in the USA**

Please use only the valid version of the package insert provided with the kit.

This kit is intended for Research Use Only.

This kit is not intended for diagnostic purposes.

INTENDED USE

Enzyme immunoassay for determination of neopterin in human serum, plasma and urine.

TEST PRINCIPLE

Solid phase enzyme-linked immunosorbent assay (ELISA) based on the basic principle of a competitive ELISA. An unknown amount of antigen in the sample and a fixed amount of enzyme labelled antigen compete for the antibody-binding sites (rabbit-anti-neopterin). Both antigen-antibody complexes bind to the wells of the microtiter strips coated with a goat-anti-rabbit antibody. Unbound antigen is removed by washing. The intensity of the color developed after the substrate incubation is inversely proportional to the amount of antigen in the sample. Results of samples can be determined directly using the standard curve.

WARNINGS AND PRECAUTIONS

1. For research use only. For professional use only.
2. Before starting the assay, read the instructions completely and carefully. Use the valid version of the package insert provided with the kit. Be sure that everything is understood.
3. In case of severe damage of the kit package please contact DRG or your supplier in written form, latest one week after receiving the kit. Do not use damaged components in test runs, but keep safe for complaint related issues.
4. Obey lot number and expiry date. Do not mix reagents of different lots. Do not use expired reagents.
5. Follow good laboratory practice and safety guidelines. Wear lab coats, disposable latex gloves and protective glasses where necessary.
6. Reagents of this kit containing hazardous material may cause eye and skin irritations. See MATERIALS SUPPLIED and labels for details. Material Safety Data Sheets for this product are available upon request.
7. Chemicals and prepared or used reagents have to be treated as hazardous waste according to national biohazard and safety guidelines or regulations.
8. Avoid contact with Stop solution. It may cause skin irritations and burns.
9. All reagents of this kit containing human serum or plasma have been tested and were found negative for HIV I/II, HBsAg and HCV. However, a presence of these or other infectious agents cannot be excluded absolutely and therefore reagents should be treated as potential biohazards in use and for disposal.

CE

Revised 2 Feb. 2011 rm (Vers. 12.1) **RUO in the USA**

STORAGE AND STABILITY

The kit is shipped at ambient temperature and should be stored at 2-8°C. Keep away from heat or direct sun light. The storage and stability of specimen and prepared reagents is stated in the corresponding chapters.

The microtiter strips are stable up to the expiry date of the kit in the broken, but tightly closed bag when stored at 2–8°C.

SPECIMEN COLLECTION AND STORAGE

Serum, Plasma (EDTA)

The usual precautions for venipuncture should be observed. It is important to preserve the chemical integrity of a blood specimen from the moment it is collected until it is assayed. Do not use grossly hemolytic, icteric or grossly lipemic specimens. Do not use specimens containing NaN_3. Samples appearing turbid should be centrifuged before testing to remove any particulate material.

Storage:	2-8°C	≤ -20°C (Aliquots)	Keep away from heat or direct sun light. Avoid repeated freeze-thaw cycles.
Stability:	72 h	6 mon	

Urine

It is possible to use spontaneous as well as 24 h urine. The total volume of urine excreted during a 24 h period should be collected and mixed in a single bottle. Preservation is not necessary. Determine total volume for calculation of results. **Mix and centrifuge samples before use in the assay.**

Storage:	2-8°C	≤ -20°C (Aliquots)	Keep away from heat or direct sun light. Avoid repeated freeze-thaw cycles.
Stability:	72 h	6 mon	

CE

Revised 2 Feb. 2011 rm (Vers. 12.1) **RUO in the USA**

MATERIALS SUPPLIED

Quantity	Symbol	Component
1 x 12 x 8	MTP	**Microtiter Plate** Break apart strips. Coated with anti-rabbit IgG (goat, polyclonal).
1 x 5 mL	ANTISERUM	**Neopterin Antiserum** Ready to use. Contains: Antiserum (rabbit), phosphate buffer, stabilizers.
1 x 0.1 mL	ENZCONJ CONC	**Enzyme Conjugate**, Concentrate (201x) **Store protected from light.** Contains: Neopterin conjugated to peroxidase, phosphate buffer, stabilizers.
6 x 0.5 mL	CAL A-F	**Standard A-F** 0; 1.35; 4.0; 12.0; 37.0; 111 nmol/L Ready to use. Contains: Neopterin, phosphate buffer, stabilizers.
2 x 0.5 mL	CONTROL 1+2	**Control 1+2** Ready to use. Concentrations / acceptable ranges see QC Certificate.
1 x 18 mL	ASSAYBUF	**Assay Buffer** Ready to use. Contains: phosphate buffer, BSA, stabilizers.
1 x 50 mL	WASHBUF CONC	**Wash Buffer**, Concentrate (20x) Contains: phosphate buffer, Tween, stabilizers.
1 x 17 mL	TMB SUBS	**TMB Substrate Solution**, Ready to use Contains: TMB, Buffer, stabilizers.
1 x 17 mL	TMB STOP	**TMB Stop Solution** Ready to use 1 M H_2SO_4.
1 x	FOIL	**Adhesive Foil** 1 x black;

MATERIALS REQUIRED BUT NOT SUPPLIED

1. Micropipettes (Multipette Eppendorf or similar devices, < 3% CV). Volumes: 10; 50; 100; 1000 µL
2. Vortex mixer
3. Orbital shaker (500 rpm)
4. 8-Channel Micropipettor with reagent reservoirs
5. Wash bottle, automated or semi-automated microtiter plate washing system
6. Microtiter plate reader capable of reading absorbance at 450 nm (reference wavelength 600-650 nm)
7. Bidistilled or deionised water
8. Paper towels, pipette tips and timer

CE

Revised 2 Feb. 2011 rm (Vers. 12.1) **RUO in the USA**

PROCEDURE NOTES

1. Any improper handling of samples or modification of the test procedure may influence the results. The indicated pipetting volumes, incubation times, temperatures and pretreatment steps have to be performed strictly according to the instructions. Use calibrated pipettes and devices only.
2. Once the test has been started, all steps should be completed without interruption. Make sure that required reagents, materials and devices are prepared ready at the appropriate time. Allow all reagents and specimens to reach room temperature (18-25 °C) and gently swirl each vial of liquid reagent and sample before use. Mix reagents without foaming.
3. Avoid contamination of reagents, pipettes and wells/tubes. Use new disposable plastic pipette tips for each component and specimen. Do not interchange caps. Always cap not used vials. Do not reuse wells/tubes or reagents.
4. Some components contain ≤ 250 µL solution. Take care that the solution is completely on the bottom of the vial before opening.
5. It is advised to determine samples in duplicate to be able to identify potential pipetting errors.
6. Use a pipetting scheme to verify an appropriate plate layout.
7. Incubation time affects results. All wells should be handled in the same order and time sequences. It is recommended to use an 8-channel Micropipettor for pipetting of solutions in all wells.
8. Microplate washing is important. Improperly washed wells will give erroneous results. It is recommended to use a multichannel pipette or an automatic microplate washing system. Do not allow the wells to dry between incubations. Do not scratch coated wells during rinsing and aspiration. Rinse and fill all reagents with care. While rinsing, check that all wells are filled precisely with Wash Buffer, and that there are no residues in the wells.
9. Humidity affects the coated wells/tubes. Do not open the pouch until it reaches room temperature. Unused wells/tubes should be returned immediately to the resealed pouch including the desiccant.

CE

Revised 2 Feb. 2011 rm (Vers. 12.1) **RUO in the USA**

PRE-TEST SETUP INSTRUCTIONS

⚠ The contents of the kit for 96 determinations can be divided into 3 separate runs.
The volumes stated below are for one run with 4 strips (32 determinations).

Preparation of lyophilized or concentrated components

Dilute/ dissolve	Component	with	Diluent	Relation	Remarks	Storage	Stability
15 mL	WASHBUF CONC	285 mL	bidist. water	1:20		2-8°C	1 mon
25 µL	ENZCONJ CONC	5 mL	ASSAYBUF	1:201	Store protected from light.	2-8°C	24 h

Dilution of Samples

Sample	to be diluted	with	Relation	Remarks
Serum	no			Avoid direct sun light.
Urine	generally	ASSAYBUF	1:101	e.g. 10 µL + 1000 µL Avoid direct sun light.

Samples containing concentrations higher than the highest standard have to be diluted further.

⚠ Samples from patients treated with ATG (anti-T lymphocyte globulin from rabbit) after transplantation will cause erroneous high results. This effect can be avoided by a pre-incubation of the samples:
Pipette 100 µL of serum into a Sarstedt or glass tube and add 200 µL of Assay Buffer. Close tubes (use pierced stopper for glass tubes) and incubate for 10 min in a water bath at 95 - 100 °C. Vortex and withdraw 10 µL of the gel for the assay. Results have to be multiplied 3-fold.

TEST PROCEDURE

MANUAL PROCEDURE

1. Pipette **10 µL** of each **Standard, Control, serum sample and diluted urine sample** into the respective wells of the Microtiter Plate.
2. Pipette **100 µL** of freshly prepared **Enzyme Conjugate (1:201)** into each well.
3. Pipette **50 µL** of **Neopterin Antiserum** into each well.
4. Cover plate with black adhesive foil. **Incubate 90 min** at **RT (18-25°C)** on an orbital shaker (500 rpm) in the dark.
5. Remove adhesive foil. Discard incubation solution. Wash plate **4 x** with **300 µL** diluted **Wash Buffer**. Remove excess solution by tapping the inverted plate on a paper towel.

6. For adding of Substrate and Stop Solution use, if available, an 8-channel Micropipettor. Pipetting should be carried out in the same time intervals for Substrate and Stop Solution. Use positive displacement and avoid formation of air bubbles.
7. Pipette **150 µL** of **TMB Substrate Solution** into each well.
8. **Incubate 10 min** at **RT (18-25°C)**.
9. Stop the substrate reaction by adding **150 µL** of **TMB Stop Solution** into each well. Briefly mix contents by gently shaking the plate.
10. **Measure** optical density with a photometer at **450 nm** (Reference-wavelength: 600-650 nm) within **15 min.**

Protocols for commercially available devices e.g. Triturus from Grifols, DSX from Dynex, DS2 from Dynex, Tecan Genesis RSP, BEP3 and BEP2000 from Dade Behring etc. can be provided. Please contact us if you want to automatize your ELISA.

QUALITY CONTROL

The test results are only valid if the test has been performed following the instructions. Moreover the user must strictly adhere to the rules of GLP (Good Laboratory Practice) or other applicable standards/laws. All kit controls must be found within the acceptable ranges as stated on the vial labels. If the criteria are not met, the run is not valid and should be repeated. Each laboratory should use known samples as further controls.
It is recommended to participate at appropriate quality assessment trials.
In case of any deviation the following technical issues should be proven: Expiration dates of (prepared) reagents, storage conditions, pipettes, devices, incubation conditions and washing methods.

CALCULATION OF RESULTS

The obtained OD of the standards (y-axis, linear) are plotted against their concentration (x-axis, logarithmic) either on semi-logarithmic graph paper or using an automated method. A good fit is provided with cubic spline, 4 Parameter Logisitcs or Logit-Log.
For the calculation of the standard curve, apply each signal of the standards (one obvious outlier of duplicates might be omitted and the more plausible single value might be used).
The concentration of the samples can be read directly from the standard curve.
Due to the dilution of urine samples the urine values obtained have to be multiplied by the factor 101.
Samples showing concentrations above the highest standard have to be diluted as described in PRE-TEST SETUP INSTRUCTIONS and reassayed.

CE

Revised 2 Feb. 2011 rm (Vers. 12.1) **RUO in the USA**

Conversion:
Neopterin (nmol/L) x 0.253 = ng/mL

Typical Calibration Curve (Example. Do not use for calculation!)

Standard	Neopterin (nmol/L)	Mean OD	OD/OD_{max}
A	0.00	1.942	100.0
B	1.35	1.713	88.2
C	4.00	1.283	66.1
D	12.0	0.761	39.2
E	37.0	0.412	21.2
F	111	0.237	12.2



CE

Revised 2 Feb. 2011 rm (Vers. 12.1) **RUO in the USA**

PRODUCT LITERATURE REFERENCES

1. Wachter H, Fuchs D, Hausen A, Reibnegger G, Weiss G, Werner ER, Werner-Felmayer G. Neopterin: Biochemistry - Methods - Clinical Application. Walter de Gruyter Berlin, New York, (1992)
2. Westermann J, Thiemann F, Gerstner L, Tatzber F, Kozák I, Bertsch T, Krüger C. Evaluation of a New Simple and Rapid Enzyme-Linked Immunosorbent Assay Kit for Neopterin Determination. Clin Chem Lab Med, 38 (4): 345-353 (2000)
3. X Garcia-Moll, D Cole, E Zouridakis, JC Kaski. Increased serum Neopterin: a marker of coronary artery disease activity in woman. Heart 83:346-350 (2000)
4. Smith D, Zouridakis, E, Mariani M, Fredericks S, Cole D, Kaski J. Neopterin levels in patients with coronary artery disease are independent of Chlamydia pneumoniae seropositivity. Am Heart J, 146 (1): 69-74 (2003)
5. B. Inci Fisenk, Durdal US, Osman I. Ozcebe & Gulsen Hascelik. The value of increased Neopterin levels in reducing transfusion-transmitted virus infections: Detection of a donation from a HbsAg positive chronic carrier by screening of neopterin in Turkish blood donors. Scandinavian Journal of Infectious disease, 37:599-604 (2005)
6. Michaela Bayer, Sven Schmitz, Jürgen Westermann, Frank Thiemann, Ralf Edelmann, Claudia Szakacs, Gerhardt Lanzer, Jens Blecken. Evaluation of a New-Linked Immunosorbent Assay for the Determination of Neopterin. Clin Lab. 51 (2005)
7. R. Weimer, C. Süsal, S. Yildiz, A. Staak, S. Pelzl, F. Renner, H. Dietrich, V. Daniel, S. Kamali-Ernst, W. Padberg, G. Opelz. Post-Transplant sCD30 and Neopterin as Predictors of Chronic Allograft Nephropathy: Impact of Different Immunosuppressive Regimes. Amercan Journal of Transplantation (2006)
8. Cangel P.Y. Chan, Junet W.Y. Choi , Kai-Yuan Cao, Ming Wang, Yang Gao, Duan-Hua Zhou, Biao Di, Hui-Fang Xu, Man-Fai Leung, Andreas Bergmann, Matthias Lehmann, Yong-Mei Nie, George W.H. Cautherley, Dietmar Fuchs, Reinhard Renneberg, Bo-Jian Zheng. Detection of serum neopterin for early assessment of dengue virus infection. Journal of Infection (2006)
9. Douglas T. Johnston, Marios Gagos, Nicolas Raio, Louis Ragolia, David Shenouda, Mark A. Davis-Lorton, Joshua R. De Leon. Alterations in serum neopterin correlate with thrombolysis in myocardial infarction risk scores in acute coronary syndromes. Coronary artery disease 2006, 17:511-516
10. SP Gieseg, EM Crone, EA Flavall, Z Amit. Potential to inhibit growth of atherosclerotic plaque development through modulation of macrophages neopterin/ 7,8-dihydroneopterin synthesis. British Journal of Pharmacology (2007)
11. Kausik K. Ray, David A. Morrow, Marc S. Sabatine, Amy Shui, Nader Rifai, Christopher P. Cannon, Eugene Braunwald. Circulation 2007; 115; 3071:3078